Released Aug 8, 2017, after the close
10-Q filed Aug 8, 2017, 39 days after period end · 0001232524-17-000134
Q2 2017 · 10-Q
Revenue$394.39M$394.39M +3.5% vs Q2 2016+4.9% vs Q1 2017
Net Income$105.60M$105.60M −7.8% vs Q2 2016+22.1% vs Q1 2017
EPS Diluted$1.72$1.72 −7.0% vs Q2 2016+22.0% vs Q1 2017
Gross Profit$360,983,000+1.6%
Operating Income$165,043,000−2.2%
Operating Cash Flowderived$135,091,000+6.4%
Free Cash Flowderived$126,940,000+2.8%
Margins · derived
Gross margin91.5%−1.6 pt vs Q2 2016
Operating margin41.8%−2.4 pt vs Q2 2016
Net margin26.8%−3.3 pt vs Q2 2016
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2017 | Q2 2016 | Q2 2015 | Q2 2014 |
|---|---|---|---|---|
| Revenue | $394.39M | $381.16M | $333.75M | $291.23M |
| Net Income | $105.60M | $114.50M | $88.11M | $43.66M |
| EPS Diluted | $1.72 | $1.85 | $1.40 | $0.70 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR